A 78 Week Open Label Extension to Trials Assessing the Safety and Efficacy of BI 10773 as Monotherapy or in Combination With Metformin in Type 2 Diabetic Patients
A 78 Week Open Label Extension to Trials Assessing the Safety and Efficacy of BI 10773 as Monotherapy or in Combination With Metformin in Type 2 Diabetic Patients
The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2 different doses compared to Metformin or to Sitagliptin given for 78 weeks in different modalities of treatment in patients with type 2 diabetes mellitus.
Inclusion criteria:
Exclusion criteria:
Clearwarter, Florida, United States
Saint Ingbert/Oberwürzbach, Germany
Baia Mare Maramures, Romania
Pucheon, South Korea
L'Hospitalet de Llobregat (Barcelona), Spain
Palma Mallorca, Spain
Palma Mallorca, Spain
Taichun, Taiwan